These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29151972)

  • 1. Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis.
    Wu SG; Zhang WW; Sun JY; Li FY; Lin HX; Chen YX; He ZY
    J Cancer; 2017; 8(18):3849-3855. PubMed ID: 29151972
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database.
    Hessler LK; Molitoris JK; Rosenblatt PY; Bellavance EC; Nichols EM; Tkaczuk KHR; Feigenberg SJ; Bentzen SM; Kesmodel SB
    Ann Surg Oncol; 2017 Oct; 24(10):2907-2914. PubMed ID: 28766198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary lymph node dissection plus radiotherapy may be an optimal strategy for patients with occult breast cancer.
    Li L; Zhang D; Wen T; Wu Y; Lv D; Zhai J; Ma F
    J Natl Cancer Cent; 2022 Dec; 2(4):198-204. PubMed ID: 39036544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study.
    Sohn G; Son BH; Lee SJ; Kang EY; Jung SH; Cho SH; Baek S; Lee YR; Kim HJ; Ko BS; Yu ; Lee JW; Ahn SH
    J Surg Oncol; 2014 Sep; 110(3):270-4. PubMed ID: 24863883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Benefit of Radiotherapy in Patients with Occult Breast Cancer: A Population-Based Analysis of the SEER Database.
    Kim BH; Kwon J; Kim K
    Cancer Res Treat; 2018 Apr; 50(2):551-561. PubMed ID: 28602055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconceptualizing the clinicopathological features, locoregional therapy and prognostic factors of occult breast cancer in the era of molecular subtyping.
    Ye X; Yang L; He Q; Lin X; Wang J; Cui R; Xu C
    Women Health; 2023 Feb; 63(2):105-114. PubMed ID: 36576239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best treatment options for occult breast cancer: A meta-analysis.
    Wang R; Yang HX; Chen J; Huang JJ; Lv Q
    Front Oncol; 2023; 13():1051232. PubMed ID: 37251927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy analysis of radiotherapy combined with surgery for locally advanced rectal mucinous adenocarcinoma: a retrospective study based on data of Surveillance, Epidemiology, and End results population].
    Zhang Y; Wang X; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Sun Y; Ye D
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):85-93. PubMed ID: 30703799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of optimal surgical management for occult breast carcinoma: Mastectomy or quadrantectomy?
    Huang Y; Wu H; Luo Z
    Medicine (Baltimore); 2017 Dec; 96(52):e9490. PubMed ID: 29384945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study.
    Ge LP; Liu XY; Xiao Y; Gou ZC; Zhao S; Jiang YZ; Di GH
    Cancer Manag Res; 2018; 10():4381-4391. PubMed ID: 30349371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological features, psychological status, and prognosis of 33 patients with occult breast cancer.
    Wang HM; Yu AY; Li LL; Ma LY; Cao MH; Yang YL; Qin XB; Tang JJ; Han ZX
    World J Psychiatry; 2024 Jan; 14(1):76-87. PubMed ID: 38327892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
    Fu Y; Chung D; Cao MA; Apple S; Chang H
    Ann Surg Oncol; 2014 Dec; 21(13):4109-23. PubMed ID: 25081336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy and Male Breast Cancer: A Population-based Registry Analysis.
    Madden NA; Macdonald OK; Call JA; Schomas DA; Lee CM; Patel S
    Am J Clin Oncol; 2016 Oct; 39(5):458-62. PubMed ID: 24781343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer.
    He M; Tang LC; Yu KD; Cao AY; Shen ZZ; Shao ZM; Di GH
    Eur J Surg Oncol; 2012 Nov; 38(11):1022-8. PubMed ID: 22959166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.
    Stauder MC; Caudle AS; Allen PK; Shaitelman SF; Smith BD; Hoffman KE; Buchholz TA; Chavez-Macgregor M; Hunt KK; Meric-Bernstam F; Woodward WA
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):637-44. PubMed ID: 27681760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
    Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
    Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study.
    Zhao Z; Zhang T; Yao Y; Lu X
    BMC Surg; 2022 Apr; 22(1):143. PubMed ID: 35430796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective application of axillary node dissection in elderly women with early breast cancer.
    Aziz D; Gardner S; Pritchard K; Paszat L; Holloway CM
    Ann Surg Oncol; 2007 Feb; 14(2):652-9. PubMed ID: 17151795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.